From major journals, first or last author from the Institute for Cancer Research
Barkovskaya A, Goodwin CM, Seip K, Hilmarsdottir B, Pettersen S, Stalnecker C, Engebraaten O, Briem E, Der CJ, Moestue SA, Gudjonsson T, Maelandsmo GM, Prasmickaite L(2021) Detection of phenotype-specific therapeutic vulnerabilities in breast cells using a CRISPR loss-of-function screen Mol Oncol(in press) DOI 10.1002/1878-0261.12951, PubMed 33759347
Jaiswal A, Gautam P, Pietilä EA, Timonen S, Nordström N, Akimov Y, Sipari N, Tanoli Z, Fleischer T, Lehti K, Wennerberg K, Aittokallio T(2021) Multi-modal meta-analysis of cancer cell line omics profiles identifies ECHDC1 as a novel breast tumor suppressor Mol Syst Biol, 17(3), e9526 DOI 10.15252/msb.20209526, PubMed 33750001
Seppälä TT, Dominguez-Valentin M, Crosbie EJ, Engel C, Aretz S, Macrae F, Winship I, Capella G, Thomas H, Hovig E, Nielsen M, Sijmons RH, Bertario L, Bonanni B, Tibiletti MG, Cavestro GM, Mints M, Gluck N, Katz L, Heinimann K, Vaccaro CA, Green K, Lalloo F, Hill J, Schmiegel Wet al.(2021) Uptake of hysterectomy and bilateral salpingo-oophorectomy in carriers of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report Eur J Cancer, 148, 124-133(in press) DOI 10.1016/j.ejca.2021.02.022, PubMed 33743481
Meltzer S, Torgunrud A, Abrahamsson H, Solbakken AM, Flatmark K, Dueland S, Bakke KM, Bousquet PA, Negård A, Johansen C, Lyckander LG, Larsen FO, Schou JV, Redalen KR, Ree AH(2021) The circulating soluble form of the CD40 costimulatory immune checkpoint receptor and liver metastasis risk in rectal cancer Br J Cancer(in press) DOI 10.1038/s41416-021-01377-y, PubMed 33837301
Hølmebakk T, Boye K(2021) Correction to: ASO Author Reflections: How to Identify Patients at Genuinely High Risk of Recurrence from Localized Gastrointestinal Stromal Tumor of the Stomach? Ann Surg Oncol(in press) DOI 10.1245/s10434-021-09939-3, PubMed 33829360
Johnson ML, Zvirbule Z, Laktionov K, Helland A, Cho BC, Gutierrez V, Colinet B, Lena H, Wolf M, Gottfried M, Okamoto I, van der Leest C, Rich P, Hung JY, Appenzeller C, Zhaowen S, Maag D, Luo Y, Nickner C, Vajikova A, Komarnitsky P, Bar J(2021) Rovalpituzumab Tesirine as a Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage Small Cell Lung Cancer: Results From the Phase 3 MERU Study J Thorac Oncol(in press) DOI 10.1016/j.jtho.2021.03.012, PubMed 33823285